This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Tarnowski, G. S. Articles by Stock, C. C. Search for Related Content PubMed PubMed Citation Articles by Tarnowski, G. S. Articles by Stock, C. C.

Sensitivity to Chemotherapeutic and Immunomodulating Agents of Two Mouse Lymphomas and of a Macrophage Tumor¹

Walker Laboratory, Memorial Sloan-Kettering Cancer Center, Rye, New York 10580

The effect of treatment with 15 chemotherapeutic and 10 immunomodulating agents on the growth of T-cell lymphoma EL-4, macrophage tumor J774, and B-cell lymphoma 70Z/2 of the mouse has been studied using the prolongation of median survival time of tumor-bearing hosts as an index of therapeutic effectiveness. The survival time of mice bearing 70Z/2 was prolonged more than 100% by single-agent therapy with actinomycin D, cyclophosphamide, 6-mercaptopurine, mitomycin C, and vinblastine; a similar response of J774 was produced by therapy with Adriamycin, cyclophosphamide, or 6-mercaptopurine. No chemotherapeutic agent prolonged the median survival time of mice bearing EL-4 by 100% or more. Of the immunomodulating agents, mycobacterial preparations (Bacillus Calmette-Guérin or interphase material), Corynebacterium parvum, and polyinosinic-polycytidylic acid moderately prolonged the survival time of mice bearing J774 or 70Z/2; the EL-4 lymphoma was refractory to all 10 immunomodulating agents.

¹ Supported in part by National Cancer Institute Grants CA-08748, CA-18856-02, and CA-24300.

² To whom requests for reprints should be addressed, at the Donald S. Walker Laboratory, Sloan-Kettering Institute for Cancer Research, 145 Boston Post Road, Rye, N. Y. 10580.

Received 7/ 2/79. Accepted 7/ 9/79.